Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Iroko Holdings, managing member of Iroko Pharmaceuticals and Iroko Cardio, have appointed Bert van den Bergh as an executive board member. Together with the Iroko team and an advisory team, Mr Bergh is expected to focus on the commercialisation of Aggrastat (tirofiban hydrochloride), a GP IIB/IIIA inhibitor, in territories outside the US.
Subscribe to our email newsletter
Mr Bergh brings with him 30 years career experience as president of neuroscience products at Eli Lilly, as well as general manager of five affiliates on four continents in markets like Germany and the UK, start-up businesses in markets like Indonesia.
During his term as president of Eli Lilly’s European Operations, Mr Bergh developed its pan-European business unit to serve the interventional cardiology marketplace for the commercialisation of Eli Lilly’s market leading GP IIB/IIIA inhibitor in Europe.
Mr Bergh said: “Together we will commercialise Aggrastat (tirofiban hydrochloride) in Europe and the other regions of the world. I am convinced that Aggrastat (tirofiban hydrochloride) provides an opportunity to deliver relevant patient benefits to clinicians, payers and purchasing organisations.
“I look forward to working with all stake holders at Iroko, our management team, our customers and in particular our commercial partners, to determine the best path forward for Aggrastat (tirofiban hydrochloride).”